PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
From:
Published online 2012 July 2. doi: 10.2147/BTT.S20659

Table 5

Odds of progression of radiographic damage ranked by effect size: monotherapy versus methotrexate

MedicationReferencePatients progressingOR (95% CI)

TreatmentPlacebo
TocilizumabNishimoto et al1844%61%0.50 (0.31, 0.82)
AdalimumabBreedveld et al1449%63%0.57 (0.37, 0.89)
EtanerceptKlareskog et al632%43%0.63 (0.42, 0.93)
Bathon et al528%40%0.58 (0.38, 0.88)
Pooled0.61 (0.45, 0.81)
GolimumabEmery et al15
GO-BEFORE15
39%46%0.76 (0.98, 1.23)
Emery et al15
GO-FORWARD15
34%31%0.89 (0.49, 1.61)
Pooled0.81 (0.56, 1.17)

Note: Bold text indicates pooled results for each agent.

Abbreviations: CI, confidence interval; OR, odds ratio.